Eli Lilly & Co. (LLY) announced Tuesday morning that it has made a change to the primary endpoint for the Phase 3 study of solanezumab, in people with mild Alzheimer's dementia. Originally the study had co-primary endpoints of cognition and function, but will now have single primary endpoint of cognition.
from RTT - Before the Bell http://ift.tt/1U7bzUg
via IFTTT
No comments:
Post a Comment